Introduction:

Early diagnosis of atrophic gastritis and eradication of Helicobacter pylori are key strategies for its prevention. This pilot study evaluated the usefulness of GastroPanel®, a non-invasive screening test for risk factors.

Materials and methods:

A descriptive, correlational, and non-experimental study was conducted with 25 patients who underwent upper gastrointestinal endoscopy with Yagi AB classification and biopsies for histopathological analysis. GastroPanel® was performed, and its results were compared quantitatively and qualitatively with the histopathological findings.

Outcomes:

Females predominated, with a mean age of 78 years. Intestinal metaplasia was absent in 72% of patients, and Helicobacter pylori was detected in 28%. GastroPanel® showed variable ranges of gastrin and pepsinogen. Quantitatively, GastroPanel® showed low performance for diagnosing intestinal atrophy (AUC 0.51) and metaplasia (AUC 0.47), but qualitatively demonstrated 78% sensitivity and 71% specificity for intestinal metaplasia. For Helicobacter pylori, it showed 86% sensitivity and 89% specificity.

Conclusions:

GastroPanel® is a promising diagnostic tool. It does not replace biopsy, but it has high performance in the non-invasive detection of Helicobacter pylori in low-risk patients according to ABC criteria.